肝内胆管癌（ICC）是继肝细胞癌（HCC）之后第二常见的肝脏原发性恶性肿瘤。手术切除仍然是 ICC 唯一可能治愈的治疗方法。但由于其恶性程度高、术后复发率高，ICC的预后普遍较差，目前根治性手术后的辅助治疗尚缺乏标准化方法。本文旨在通过回顾性研究和近年来的临床试验，探讨ICC术后的辅助治疗策略。考虑到高复发率和改进治疗方法以提高患者预后的需要，该分析重点关注 ICC 术后管理的有效性、挑战和潜在发展。此外，我们还讨论了已探索的各种类型的辅助治疗，包括化疗、放射治疗和靶向治疗。目标是对当前情况进行全面概述，并强调未来研究的有希望的方向，以提高 ICC 患者的生存率和生活质量。版权所有 © 2024 Sun、Jiang、Duan 和guan。

Intrahepatic cholangiocarcinoma (ICC) is the second most common primary malignancy of the liver, following hepatocellular carcinoma (HCC). Surgical resection remains the only potentially curative treatment for ICC. However, due to its high malignancy and propensity for postoperative recurrence, the prognosis for ICC is generally poor, and there is currently little standardized approach for adjuvant therapy following curative surgery. This article aims to explore adjuvant treatment strategies for ICC post-curative surgery by reviewing retrospective studies and clinical trials conducted in recent years. The analysis focuses on the effectiveness, challenges, and potential developments in the management of ICC post-surgery, considering the high recurrence rates and the need for improved therapeutic approaches to enhance patient outcomes. Additionally, we discuss the various types of adjuvant treatments that have been explored, including chemotherapy, radiation therapy, and targeted therapies. The goal is to provide a comprehensive overview of the current landscape and highlight promising directions for future research to improve survival and quality of life for ICC patients.Copyright © 2024 Sun, Jiang, Duan and Guan.